• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Cell Morphomics Reveals Shared Structural Pathology Across Diverse Neurological Diseases in Human Models

by
November 17, 2026
in Health
Reading Time: 5 mins read
0
Cell Morphomics Reveals Shared Structural Pathology Across Diverse Neurological Diseases in Human Models

Cell Morphomics Reveals Shared Structural Pathology Across Diverse Neurological Diseases in Human Models

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A systematic review of high-content imaging across human cellular models has synthesized how quantitative cellular morphology uncovers coordinated subcellular structural changes spanning eight neurodegenerative and neuropsychiatric disorders. The analysis, which evaluated thirty-three eligible peer-reviewed studies published between October 2020 and October 2025 across PubMed, Embase, and Scopus, positions cell morphomics as a scalable intermediate phenotype connecting genetic perturbations and molecular abnormalities directly to functional consequences. Rather than examining isolated cellular pathways or single organelles in isolation, the synthesized research demonstrates that diseases such as Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, hereditary spastic paraplegia, Huntington’s disease, dominant optic atrophy, schizophrenia, and autism spectrum disorder express pathology through complex structural shifts across multiple internal compartments, notably the mitochondria, endolysosomal system, cytoskeleton, and nucleus.

To assemble the evidence base, investigators filtered the literature according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, focusing specifically on two-dimensional high-throughput imaging workflows conducted in human-derived cellular models. Studies relying solely on non-human systems, non-primary research, or three-dimensional models such as organoids and spheroids were excluded unless human data were incorporated. Across the final corpus of thirty-three studies, experimental systems spanned patient-derived primary dermal fibroblasts, induced pluripotent stem cell-derived neural lineages, immortalized cell lines, and isogenic models edited with CRISPR-Cas9 to isolate single variant contributions against uniform backgrounds. The authors observed that while three-dimensional tissue architectures provide end-stage diagnostic features of neuropathology in fixed post-mortem specimens, living human cellular models provide an essential complementary window into active cellular stress responses, organelle dynamics, and compound sensitivity.

Technical foundations across the reviewed studies rely on two primary morphometric strategies: segmentation-based feature extraction and direct image representation learning. In segmentation-based profiling, software platforms such as CellProfiler, Cellpose, or commercial vendor tools measure hundreds to thousands of predefined geometric parameters per cell, describing shape, signal intensity distributions, textural smoothness or granularity, and cytoskeletal or organelle network connectivity. In contrast, representation learning deploys deep learning architectures, such as convolutional neural networks and vision transformers, to extract latent embeddings directly from unsegmented or raw multi-channel fluorescence imagery. While segmentation pipelines offer direct biological interpretability by mapping alterations to specific labeled organelles, learned representation models capture subtle, spatially distributed patterns across cellular contexts without requiring predefined measurements, frequently yielding higher accuracy in distinguishing diseased cell lines from controls.

In Parkinson’s disease models, coordinated morphological alterations in mitochondria and lysosomes emerge as the most consistent discriminatory features across multiple cell types and genetic backgrounds. In midbrain dopaminergic neurons carrying LRRK2 G2019S or SNCA triplication mutations, high-content imaging identified reduced mitochondrial membrane potential, decreased lysosomal area, elevated phosphorylated alpha-synuclein, and simplified dendritic branches. Pharmacological testing demonstrated that these structural defects could be quantitatively tracked during drug perturbation, where LRRK2 kinase inhibitors such as MLi-2 and PFE-360, alongside protein kinase C agonists, restored organelle parameters toward control states. Similarly, large-scale chemical screening across more than one thousand compounds in SNCA triplication dopaminergic neurons prioritized candidates such as Tyrphostin A9, which normalized multi-dimensional morphomic signatures while concurrently reducing toxic alpha-synuclein species and improving cellular bioenergetics.

Peripheral models of Parkinson’s disease reflect similar organelle-level signatures, confirming that structural alterations are not confined to post-mitotic neurons. In primary dermal fibroblasts obtained from ninety-one Parkinson’s disease patients and matched healthy controls, machine learning classifiers trained on Cell Painting image embeddings separated both sporadic cases and LRRK2 mutation carriers from controls without requiring preselected features. Parallel investigations linked these peripheral cellular phenotypes directly to patient physiology: in recently diagnosed patients, fibroblast mitochondrial membrane potential, elevated lysosomal counts, and mitochondrial proliferation correlated with in vivo brain bioenergetics measured by phosphorus-31 magnetic resonance spectroscopy in the putamen. Furthermore, single-cell morphomic analyses revealed that while average mitochondrial metrics across large sporadic cohorts may appear preserved, patient subgroups exhibit pronounced variance, identifying distinct mitochondria-deficient or lysosome-burdened mechanistic profiles with differing drug responses.

Studies in Alzheimer’s disease similarly highlight the capacity of quantitative morphology to resolve trafficking failures, cytoskeletal stress, and organelle instability across distinct cell models. In neural progenitor cells deficient in the endosomal sorting receptor SORL1, automated imaging identified alterations in four hundred and eight of seven hundred and fifty-six morphometric parameters, allowing neural network classifiers to distinguish mutant from isogenic wild-type lines with greater than ninety-nine percent accuracy. A screen of three hundred and thirty compounds subsequently detected sixteen small molecules that partially shifted the knockout profile back toward wild-type geometry. In familial Alzheimer’s disease neurons carrying PSEN1 or PSEN2 mutations, live-cell longitudinal imaging demonstrated allele-dependent mitochondrial fragmentation around twelve days in vitro, preceding neurite degeneration and tracking functional respiratory deficits, whereas APP mutant neurons exhibited comparatively milder mitochondrial changes.

Beyond classical neurodegenerative disorders, cell morphomics provides detailed phenotypic resolution in amyotrophic lateral sclerosis and hereditary spastic paraplegia. In motor neurons derived from patients with C9ORF72 repeat expansions, long-term live tracking revealed late-onset failure of axonal transport for both mitochondria and lysosomes, leading to accumulated DNA damage and apoptosis by day eighty. In hereditary spastic paraplegia, high-content profiling of primary fibroblasts from SPAST and SPG7 patients successfully classified genotypes based on acetylated alpha-tubulin and mitochondrial organization, while detecting mitochondrial stress responses with ten-fold greater sensitivity than traditional aspect-ratio metrics. In cortical neurons derived from SPG7 patients, pharmacological intervention with the compound Bz-423 restored mitochondrial membrane potential and rescued neurite branching complexity to normal levels, illustrating how morphometric endpoints verify structural recovery.

The reviewed literature also establishes quantitative cellular profiling in Dominant Optic Atrophy, Huntington’s disease, and neurodevelopmental conditions. In OPA1-mutant fibroblasts, machine learning categorized mitochondrial networks into distinct structural configurations, allowing a functional genetic screen of more than fifteen hundred mitochondrial genes to identify PGS1 knockdown as a selective suppressor of mitochondrial fragmentation. In Huntington’s disease fibroblasts, progressive loss of apical actin cap fibers, rising nuclear circularity, and mitochondrial fragmentation tracked clinical severity from premanifest to severe stages, with the antioxidant MitoQ partially reversing these mechanical and structural deficits. In neurodevelopmental contexts, such as the 22q11.2 deletion syndrome and monogenic autism models, quantitative imaging coupled with transcriptomics linked disrupted cell-cell adhesion pathways to aberrant organelle positioning and reduced neurite outgrowth.

Despite demonstrating that morphomic analysis can identify shared cellular vulnerabilities and track therapeutic response, the systematic review emphasizes several critical methodological and interpretive limitations across the current literature. First, because morphological features capture aggregated cellular responses, static images cannot independently determine whether an observed structural change represents a primary disease driver, a downstream byproduct, or a protective compensatory adaptation. Furthermore, shared morphological endpoints across different diseases—such as nuclear rounding and mitochondrial fragmentation—do not necessarily demonstrate identical underlying mechanisms, as they may reflect common convergent stress responses or pathways leading to cell death. The investigators noted substantial heterogeneity in imaging instruments, dye combinations, and normalisation methods, alongside typically small sample sizes in rare genetic cohorts, which prevented a formal quantitative meta-analysis. In one large study examining over four hundred fibroblast lines across sporadic, C9ORF72, and SOD1 amyotrophic lateral sclerosis, baseline classification achieved only marginal accuracy above chance, highlighting that peripheral morphomic signals remain subtle in genetically heterogeneous populations.

Looking forward, the authors conclude that advancing cell morphomics from experimental profiling into validated clinical translation requires fundamental adjustments in study design. Rather than relying on simple case-versus-control separations against healthy individuals, future studies must evaluate whether morphomic algorithms can discriminate between clinically overlapping neurodegenerative diseases and identify mechanistic patient subgroups within idiopathic cohorts. Connecting cellular and organelle metrics prospectively to longitudinal clinical trajectories, fluid biomarkers such as cerebrospinal fluid proteins, and advanced neuroimaging will be essential to establish clinical utility. Standardizing multi-well acquisition pipelines, controlling for technical batch effects with donor-aware validation splits, and pairing high-dimensional structural data with orthogonal functional assays will ultimately allow researchers to deploy cell morphomics as an objective, human-relevant framework for targeted drug discovery and patient stratification.

Subject of Research: Systematic review of cell morphomics and quantitative cellular morphology in human models of neurodegenerative and neuropsychiatric diseases

Article Title: Quantitative cellular morphology in neurodegenerative and neuropsychiatric diseases: insights into disease mechanisms and therapeutic discovery

Article References: Wali, G., Sutharsan, R., Jones, H., Singh, S., & Sue, C. M. (2026). Quantitative cellular morphology in neurodegenerative and neuropsychiatric diseases: insights into disease mechanisms and therapeutic discovery. Molecular Neurodegeneration Advances, 2(1), Article 48. https://doi.org/10.1186/s44477-026-00051-y

Image Credits: AI Generated

DOI: 10.1186/s44477-026-00051-y

Keywords: cell morphomics, high-content imaging, neurodegenerative diseases, mitochondrial morphology, lysosomal dysfunction, induced pluripotent stem cells, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, hereditary spastic paraplegia, Huntington's disease, dominant optic atrophy, machine learning, phenotypic screening, organelle trafficking, cytoskeleton, deep learning

News Source: Diana Fleming. (November 17, 2026). Cell Morphomics Reveals Shared Structural Pathology Across Diverse Neurological Diseases in Human Models. Scienmag.

Tags: Alzheimer's diseaseamyotrophic lateral sclerosiscell morphomicscytoskeletondeep learningdominant optic atrophyhereditary spastic paraplegiahigh-content imagingHuntington’s diseaseinduced pluripotent stem cellslysosomal dysfunctionMachine Learningmitochondrial morphologyneurodegenerative diseasesorganelle traffickingParkinson’s diseasephenotypic screening
Share12Tweet7Share2ShareShareShare1

Related Posts

Dynamic Bone Marrow Immune Remodeling Drives Leukemia Progression in Myelodysplastic Neoplasms

Dynamic Bone Marrow Immune Remodeling Drives Leukemia Progression in Myelodysplastic Neoplasms

November 18, 2026
Reduced Infant Opioid Withdrawal Severity Associated With Care Model Expansion

Reduced Infant Opioid Withdrawal Severity Associated With Care Model Expansion

November 18, 2026

Robotic Jaw-in-a-Day Reconstructions Achieve Sub-Millimeter Implant Precision in Five-Case Study

November 18, 2026

Chronic Stroke Infarcts in Mice Exhibit Organized but Heterogeneous Adaptive Immunity

November 18, 2026

POPULAR NEWS

  • Novel Benzimidazole Schiff Bases Outperform Acarbose in Lab Glucosidase Tests

    Novel Benzimidazole Schiff Bases Outperform Acarbose in Lab Glucosidase Tests

    29 shares
    Share 12 Tweet 7
  • Latent Class Analysis Identifies Five Distinct Lifestyle and Metabolic Subtypes of Insulin Resistance

    29 shares
    Share 12 Tweet 7
  • Screening Reveals Developmental Delays in Many Pediatric Liver Transplant Recipients

    29 shares
    Share 12 Tweet 7
  • Randomized Balance Training Alters Movement Coordination Without Boosting Young Adult Stability

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dynamic Bone Marrow Immune Remodeling Drives Leukemia Progression in Myelodysplastic Neoplasms

Reduced Infant Opioid Withdrawal Severity Associated With Care Model Expansion

Robotic Jaw-in-a-Day Reconstructions Achieve Sub-Millimeter Implant Precision in Five-Case Study

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.